FindTrial
Sign In

Randomized, placebo-controlled clinical trial on the efficacy of a mouthrinse containing 0.1% benzalkoniumchloride on the reduction of intraoral viral load and infectivity in SARS-CoV-2 positive subjects (COVID-19)

Randomized, placebo-controlled clinical trial on the efficacy of a mouthrinse containing 0.1% benzalkoniumchloride on the reduction of intraoral viral load and infectivity in SARS-CoV-2 positive subjects (COVID-19)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00024454
Enrollment
50
Registered
2021-02-08
Start date
2020-10-22
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Verum: benzalkonium chloride 0.1% Group 2: Placebo: saline solution 0.9%

Sponsors

Poliklinik für Zahnerhaltung und ParodontologieUniversitätsklinikum Regensburg
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: positive SARS-CoV-2 detection within the last 72 h

Exclusion criteria

Exclusion criteria: - Indication for intubation or mechanical ventilation - severe stomatitis

Design outcomes

Primary

MeasureTime frame
Reduction of intraoral SARS-CoV-2 viral load (detection of viral load immediately before rinsing with benzalkonium chloride and 15 min and 30 min after rinsing with benzalkonium chloride by RT-PCR compared to placebo control).—

Secondary

MeasureTime frame
Reduction of intraoral SARS-CoV-2 infectivity (virus culture immediately before rinsing with benzalkonium chloride and 15 min and 30 min after rinsing with benzalkonium chloride as compared to placebo control).—

Countries

Germany

Contacts

Public ContactFabian Cieplik

Poliklinik für Zahnerhaltung und ParodontologieUniversitätsklinikum Regensburg

fabian.cieplik@ukr.de0941 944 6024

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026